REG - IQ-AI Limited - IB Broadens Quantitative Mapping

IQ-AIAnnouncement

03/05/2022 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220503:nRSC1476Ka&default-theme=true

RNS Number : 1476K  IQ-AI Limited  03 May 2022

3 May 2022

 

IQ-AI Ltd

("IQ-AI" or the "Company")

 

IB Neuro's Quantitative Mapping Method Assesses Metastatic Tumors

Study Shows DSC MRI Perfusion Distinguishes Tumor from Non-Tumor Tissue

Milwaukee - 3 May 2022:  Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI
Limited, (OTCQB: IQAIF) (LSE: IQAI), notes a recent study published in the
American Journal of Neuroradiology entitled: DSC Perfusion-Derived Fractional
Tumor Burden and Relative CBV Differentiate Tumor Progression and Radiation
Necrosis in Brain Metastases Treated with Stereotactic Radiosurgery
(http://www.ajnr.org/content/early/2022/04/28/ajnr.A7501) .

 

The retrospective study, led by Dr. Michael Iv, MD, Clinical Associate
Professor at Stanford University, used IB Software and other advanced imaging
methods to evaluate metastatic brain tumors previously treated with a very
precise form of radiation therapy called stereotactic radiosurgery. The goal
was to determine which, if any, imaging technology could reliably distinguish
between progressive tumor and radiation necrosis (non-tumor) tissue. The study
concluded that IB Neuro's dynamic susceptibility contrast magnetic resonance
imaging (DSC-MRI) perfusion-derived maps were able to make this distinction
whereas the other methods to which it was compared could not. Those other
methods included dynamic contrast enhanced (DCE) imaging, arterial spin
labeling (ASL) which is an MRI technique that uses the body's own blood as a
contrast agent to compute blood flow measurements, and positron emission
tomography (PET) which can detect metabolic differences in tissue.

 

DSC-MRI is well established as the most robust and clinically adopted method
for response assessment in high-grade (HG) primary brain tumors. Numerous
studies have demonstrated the accuracy and reproducibility of IB Neuro's DSC
platform and, specifically, its standardized measurement of relative cerebral
blood volume (rCBV) to distinguish tumor from non-tumor tissue in HG tumors.
This study is the first to replicate this method in metastatic brain tumors.
The results are positive news for treatment teams who currently must rely on
contrast-enhanced MRI to answer the basic question - is the enhancing region
tumor, or is it an effect due to treatment?

 

Metastatic brain tumors are ten times more prevalent than primary brain
tumors. This year in the US alone, it is expected that 220,000 people will be
diagnosed with a metastatic brain cancer. Moreover, advances in treatment
therapy are helping metastatic brain tumor patients live longer with improved
quality of life. Thus, this number is expected to increase over time. Up to
50% of all cancers will eventually metastasize to the brain.

 

The study referred to IB's standardized rCBV (sRCBV) measurement.
Standardization is an exclusive calibration technology that is built-in to IB
Neuro. Fully automated, standardization translates the relative MRI image
intensities to a fixed and consistent quantitative scale. This machine-learned
technology is applied once for all scanner platforms, field strengths, and
patients, and enables direct quantitative comparison between scans. It has
been shown superior over other tissue normalization techniques; all of which
require manual user input and are, therefore, less consistent and cannot be
automated. The ability to obtain quantitative sRCBV values on a per-voxel
basis differentiates IB Neuro from all other DSC-MRI platforms.

 

"This relevant and powerful study further validates our decision to develop IB
Trax™. Incorporating our quantitative Delta T1 (patent-pending) and sRCBV
maps will help neuroradiologists track and monitor brain metastases over time
and potentially boost their accuracy and efficiency," said Trevor Brown, CEO
and Chairman of IQ-AI, Ltd.

The Directors of the Company accept responsibility for the contents of this
announcement

 

-ENDS-

 

For further information, please contact:

 IQ-AI Limited

 Trevor Brown/Brett Skelly/Vinod Kaushal

 Tel: 020 7469 0930

 Peterhouse Capital Limited (Financial Adviser and Broker)

 Lucy Williams/Heena Karani

 Tel: 020 7220 9797

 

About IQ-AI Limited

IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of
Wisconsin-based Imaging Biometrics, LLC (IB), develops and provides
visualisation and analytical solutions that enable clinicians to better
diagnose and treat disease with greater confidence. Through close
collaboration with top researchers and clinicians, sophisticated advancements
are translated into platform-independent and automated software plug-ins which
can extend the base functionality of workstations, imaging systems, PACS, or
medical viewers. By design, IB's advanced visualisation software seamlessly
integrates into routine workflows. For more information about Imaging
Biometrics, visit the company's website at www.imagingbiometrics.com
(http://www.imagingbiometrics.com)

 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law
(as defined in the European Union (Withdrawal) Act 2018).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDXXLFBLELFBBK